Latest News

Aclipse Therapeutics Announces $2.2 Million Grant from UK’s Medical Research Council for Development of M102

Funding Supports Aclipse Therapeutics’ and Sheffield Institute of Translational Neuroscience’s Development of M102 in Amyotrophic Lateral Sclerosis Radnor, PA — January 26, 2021 – Aclipse

Aclipse Therapeutics Awarded AUD 1 Million Grant from FightMND

Aclipse Therapeutics was awarded an AUD 1 million (approximately US $720,000) drug development research grant from FightMND, the largest independent funder of ALS research in

Aclipse has successfully conducted the US FDA pre-IND meeting for M102

Aclipse Therapeutics has successfully conducted the US FDA pre-IND meeting for M102. The FDA has reviewed the M102 preclinical data package and confirmed the necessary